Pentagon rescinds new testosterone screening policy without explanation
The Pentagon has withdrawn a newly published clinical guidance document mandating testosterone screening for military personnel, just one day after it was released, without explaining why. The policy, championed by Defense Secretary Pete Hegseth as a way to "restore and optimise" troops' capabilities, had already drawn sharp criticism from medical experts who warned it was scientifically unfounded and potentially harmful, making its abrupt removal notable even though officials insist it will return in a revised form.
The document, "Clinical Guidance for Health and Human Performance Optimization," was published on 2 September and taken down on 3 September, alongside a statement from spokesperson Sean Parnell. It had proposed screening men aged 30 and over via questionnaire, potentially leading to blood tests and testosterone therapy, with women screened for hormonal imbalances too. The Pentagon says an interim guidance remains in place and a final version is coming soon, but gave no details on what is being changed. Experts including Dr Jason Goldman of the American College of Physicians and endocrinologist Bradley Anawalt have criticised routine testosterone screening, noting neither the Endocrine Society nor the American Urological Association endorses it, and pointing to risks such as reduced fertility, elevated cardiovascular disease and prostate cancer risk.
In short
- Pentagon pulled its new testosterone screening policy after just one day
- No explanation given; interim guidance stays until a revised version appears
- Medical experts had already criticised the screening as unscientific and risky
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
A carefully designed screening programme could help identify service members with genuine hormonal disorders that affect health or performance, allowing them to receive assessment and treatment. Supporters may argue that monitoring health proactively is part of maintaining readiness, provided tests are followed by proper clinical evaluation and treatment decisions are made individually.
The case against
Routine screening based on age and questionnaires risks medicalising normal variation and prompting unnecessary testing or testosterone treatment without clear evidence of benefit. Critics argue that treatment can cause harm, including reduced fertility, and that the policy lacked support from major medical societies; withdrawing it until the evidence and safeguards are reviewed may therefore protect personnel.
Explained simply
The Pentagon is the US defence department, which oversees the country’s armed forces. Its health guidance sets out how military medical staff should assess and treat service personnel. Testosterone is a hormone found in people of all sexes; levels vary, and treatment may be prescribed for some medical conditions.
The proposed guidance covered screening men aged 30 and over and checking women for hormone imbalances, with further tests or treatment possible. Routine screening has been questioned by medical specialists, who say it is not recommended by major US medical associations and that testosterone treatment can carry risks, including reduced fertility. Advice about troops’ health matters because it can affect individual care and how the military supports its personnel.
Government Politics Software Technology